- Oral presentation
- Open Access
Modelling residual disease volume and re-growth rates from response durations to aid in cancer trial design, interpretation and analysis, with a particular focus on breast cancer
© Gregory et al; licensee BioMed Central Ltd. 2013
- Published: 29 November 2013
- Breast Cancer
- Cancer Treatment
- Zoledronic Acid
- Residual Disease
- Trial Design
There is what might be termed an analysis gap between scientific developments and understandings at the cellular and genetic levels which lead to new cancer treatments and conventional statistical trial designs and analyses that focus on demonstrating superiority or non-inferiority.
To develop and apply multivariate mathematical/statistical models that infer cell-kill and tumour re-growth dynamics from durations of remission/response to cancer treatment.
A multivariate mathematical model was developed based on a series of assumptions about the volume and distribution of residual disease remaining after treatment at the population level, and its subsequent regrowth. This model enables the results of randomised clinical trials to be evaluated in terms of effects on these biologically relevant parameters.
Examples will be given in a number of diseases but focusing on breast cancer and the results from the AZURE trial on the use of zoledronic acid, as well as from CALGBB trial 9741 which evaluated a dose-dense treatment strategy, as proposed by Norton and Simon. Results will be presented, including quantification of the cell-killing effect of zoledronic acid from the AZURE trial, which demonstrate how the additional understandings gained from such a modelling approach can aid in trial design, interpretation of results, monitoring and analysis.
This modelling approach leads to new insights on the mechanism of action of cancer treatments which stimulates the development of new innovative approaches to treatment and more appropriate targeting of treatments to particular subgroups of patients.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.